An Overview of Modelling Techniques and Control Strategies for Modular Multilevel Matrix Converters

The Modular Multilevel Matrix Converter is a relatively new power converter topology appropriate for high-power Alternating Current (AC) to AC purposes. Several publications in the literature have highlighted the converter capabilities such as modularity, control flexibility, the possibility to include redundancy, and power quality. Nevertheless, the topology and control of this converter are relatively complex to design and implement, considering that the converter has a large number of cells and floating capacitors. Therefore multilayer nested control systems are required to maintain the capacitor voltage of each cell regulated within an acceptable range. There are no other review papers where the modelling, control systems and applications of the Modular Multilevel Matrix Converter are discussed. Hence, this paper aims to facilitate further research by presenting the technology related to the Modular Multilevel Matrix Converter, focusing on a comprehensive revision of the modelling and control strategies.Agencia Nacional de Investigacion y Desarrollo (ANID) of Chile Fondecyt 11191163 Fondecyt 1180879 Fondecyt 11190852 Fondef ID19I10370 University of Costa Rica 322-B9242 University of Santiago Dicyt 091813D

An Overview of Applications of the Modular Multilevel Matrix Converter

The modular multilevel matrix converter is a relatively new power converter topology suitable for high-power alternating current (AC)-to-AC applications. Several publications in the literature have highlighted the converter capabilities, such as full modularity, fault-redundancy, control flexibility and input/output power quality. However, the topology and control of this converter are relatively complex to realise, considering that the converter has a large number of power-cells and floating capacitors. To the best of the authors’ knowledge, there are no review papers where the applications of the modular multilevel matrix converter are discussed. Hence, this paper aims to provide a comprehensive review of the state-of-the-art of the modular multilevel matrix converter, focusing on implementation issues and applications. Guidelines to dimensioning the key components of this converter are described and compared to other modular multilevel topologies, highlighting the versatility and controllability of the converter in high-power applications. Additionally, the most popular applications for the modular multilevel matrix converter, such as wind turbines, grid connection and motor drives, are discussed based on analyses of simulation and experimental results. Finally, future trends and new opportunities for the use of the modular multilevel matrix converter in high-power AC-to-AC applications are identified.Agencia Nacional de Investigación y Desarrollo/[Fondecyt 11191163]/ANID/ChileAgencia Nacional de Investigación y Desarrollo/[Fondecyt 1180879]/ANID/ChileAgencia Nacional de Investigación y Desarrollo/[Fondecyt 11190852]/ANID/ChileAgencia Nacional de Investigación y Desarrollo/[ANID Basal FB0008]/ANID/ChileAgencia Nacional de Investigación y Desarrollo/[Fondef ID19I10370]/ANID/ChileUniversidad de Santiago/[Dicyt 091813DD]//ChileUCR::Vicerrectoría de Docencia::Ingeniería::Facultad de Ingeniería::Escuela de Ingeniería Eléctric

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701